| 刊名 | Medicinal Plant |
| 作者 | Dong LI， Ling LI， Yujie HU， JiangXiong MA， Wenlong ZHANG， Chanyuan ZHOU， Dongsheng FAN， Xiaojian GONG |
| 作者单位 | Key Laboratory for Information System of Mountainous Areas and Protection of Ecological Environment； Department of Pharmacy，the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine； College of Chemistry and Materials Engineering |
| DOI | 10.19601/j.cnki.issn2152-3924.2023.05.003 |
| 年份 | 2023 |
| 刊期 | 5 |
| 页码 | 10-18 |
| 关键词 | HPLC-ESI-HRMS, Alzheimer’s disease, Blumea balsamifera (L.) DC., Network pharmacology, Molecular docking |
| 摘要 | ［Objectives］ To expose the plausible mechanism of Blumea balsamifera (L.) DC. against Alzheimer’s disease via network pharmacology and HPLC-ESI-HRMS technology. [Methods] To begin with, HPLC-ESI-HRMS was employed to identify the components of B. balsamifera. Secondly, the potential targets of the components were identified and predicted based on chemical similarity and online databases. Thirdly, by way of topological analysis of a component-disease target interaction network, the primary candidate targets and potential active components were identified. Lastly, molecular docking analysis was used to confirm the interaction between active components and therapeutic targets. [Results] According to the final results, HPLC-ESI-HRMS identified 70 components. Out of these, 20 components were potentially biologically active, and most of them were sesquiterpenoids. According to the molecular docking results, the primary active components were appropriately coordinated with the core targets, indicating a high level of pharmacodynamic activity. Thus, the sesquiterpenes present in B. balsamifera are considered potential active ingredients having multi-target and multi-pathway effects for treating Alzheimer’s disease. [Conclusions] This research will provide a scientific reference for the future pharmacological activity and clinical application of B. balsamifera. |
